Real-world evidence (RWE) & OMOP data services

Rancho BioSciences helps pharma and biotech organizations transform real-world data (EHRs, claims, registries, patient-reported outcomes) into analysis-ready assets for regulatory submissions, health economics, and outcomes research. We specialize in OMOP Common Data Model mapping, enabling federated analytics across disparate real-world data sources.

Why it matters: Real-world evidence is increasingly important for regulatory submissions, label expansions, and payer negotiations — but RWD is notoriously messy. EHR data is riddled with inconsistent coding, missing values, and unstructured clinical notes. Extracting reliable endpoints requires both technical data engineering and clinical domain expertise.

How we work: Our team maps raw RWD to the OMOP Common Data Model, standardizing vocabularies (ICD-10, SNOMED CT, RxNorm) and building cohorts for analysis. For unstructured data (clinical notes, pathology reports), we apply NLP extraction and expert validation. We deliver OMOP-compliant databases, cohort definitions, and analysis-ready datasets suitable for regulatory submission.

Proof points: Rancho collaborated directly with the FDA on a study assessing disease progression in advanced NSCLC using Real-World Evidence, validating methods for extracting endpoints from unstructured data. We've served as the curation partner for multi-institutional collaborations requiring "honest broker" data harmonization.

Next steps: If you're building an RWE strategy but struggling with data quality and standardization — or need OMOP mapping expertise to participate in federated research networks — let's discuss your specific data sources and research questions.